利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

10 条记录 (耗时 0.026 秒)

    Transduced mesenchymal stem cells
    3.
    发明授权
    Transduced mesenchymal stem cells 失效
    转导的间充质干细胞

    公开(公告)号：US5591625A

    公开(公告)日：1997-01-07

    申请号：US158000

    申请日：1993-11-24

    申请人： Stanton L. Gerson ,  Arnold I. Caplan ,  Stephen E. Haynesworth

    发明人： Stanton L. Gerson ,  Arnold I. Caplan ,  Stephen E. Haynesworth

    IPC分类号： C12N15/867 ,  C12N5/10 ,  A61K48/00 ,  C12N5/08 ,  C12N15/86

    CPC分类号： C12N15/86 ,  C12N2740/13043

    摘要： Genetically engineered human stem cells that carry within them genes of interest particularly for the expression of physiologically or pharmacologically active proteins or for use in gene therapy. In addition to correction of genetic disorders, is the ability to introduce, in a targeted manner, additional copies of essential genes to allow expression in proliferating, nondifferentiating cells of certain gene products. These genes can be, for example, hormones matrix proteins, cytokines, adhesion molecules, detoxification enzymes and "rebuilding" proteins important in tissue repair.

    摘要翻译： 遗传工程人类干细胞，其中携带感兴趣的基因，特别是用于表达生理学或药理学活性蛋白质或用于基因治疗。 除了修正遗传疾病之外，是以目标方式引入必需基因的额外拷贝以允许在某些基因产物的增殖，非分化细胞中表达的能力。 这些基因可以是例如激素基质蛋白，细胞因子，粘附分子，解毒酶和在组织修复中重要的“重建”蛋白质。

    Screening method for controlling agranulocytosis
    6.
    发明授权
    Screening method for controlling agranulocytosis 失效
    筛选粒细胞缺乏症的方法

    公开(公告)号：US5300422A

    公开(公告)日：1994-04-05

    申请号：US802162

    申请日：1991-12-04

    申请人： Stanton L. Gerson ,  Herbert Meltzer

    发明人： Stanton L. Gerson ,  Herbert Meltzer

    IPC分类号： G01N33/94 ,  C12Q1/00 ,  G01N33/48

    CPC分类号： G01N33/948 ,  Y10S436/815

    摘要： A screening method for detecting the vulnerability of patients on clozapine therapy to developing agranulocytosis which comprises establishing the concentration of N-desmethylclozapine in the blood or bone marrow of said patient. In addition, a method of determining patient sensitivity to N-desmethylclozapine is provided which comprises collecting heparinized blood and assaying it for stem cell sensitivity to N-desmethylclozapine.

    摘要翻译： 一种用于检测患者对氯氮平治疗发展为粒细胞缺乏症的脆弱性的筛选方法，其包括确定所述患者的血液或骨髓中N-去甲基氯氮平的浓度。 此外，提供了一种确定患者对N-去甲基氯氮平的敏感性的方法，其包括收集肝素化血液并测定其对N-去甲基氯氮平的干细胞敏感性。

    Methoxyamine potentiation of temozolomide anti-cancer activity
    8.
    发明授权
    Methoxyamine potentiation of temozolomide anti-cancer activity 有权
    甲氧胺增强替莫唑胺抗癌活性

    公开(公告)号：US06465448B1

    公开(公告)日：2002-10-15

    申请号：US09373693

    申请日：1999-08-13

    申请人： Stanton L. Gerson ,  Lili Liu

    发明人： Stanton L. Gerson ,  Lili Liu

    IPC分类号： A61K3133

    CPC分类号： A61K31/33 ,  A61K31/13 ,  A61K31/445 ,  A61K31/53 ,  A61K2300/00

    摘要： This invention generally relates to novel compositions and methods for the treatment of certain cancers. Additionally, this invention relates to novel compositions and methods to screen drugs for the treatment of certain cancers. Specifically, the invention contemplates that temozolomide and methoxyamine, in combination or in sequence, shall be used as a treatment for certain tumors that are resistant to treatment by temozolomide alone.

    摘要翻译： 本发明一般涉及用于治疗某些癌症的新型组合物和方法。 此外，本发明涉及筛选用于治疗某些癌症的药物的新型组合物和方法。 具体地说，本发明考虑到组合或按顺序使用替莫唑胺和甲氧胺作为治疗单独使用替莫唑胺治疗的某些肿瘤。

    use of mutant alkyltransferases for gene therapy to protect from toxicity of therapeutic alkylating agents
    9.
    发明授权
    use of mutant alkyltransferases for gene therapy to protect from toxicity of therapeutic alkylating agents 失效
    使用突变体烷基转移酶进行基因治疗以保护治疗性烷化剂的毒性

    公开(公告)号：US5965126A

    公开(公告)日：1999-10-12

    申请号：US620969

    申请日：1996-03-25

    申请人： Anthony E. Pegg ,  Stanton L. Gerson

    发明人： Anthony E. Pegg ,  Stanton L. Gerson

    IPC分类号： A61K48/00 ,  A61K31/00 ,  A61K31/505 ,  A61K31/513 ,  A61K38/45 ,  A61P35/00 ,  C12N9/10 ,  A01N63/00

    CPC分类号： C12N9/1085 ,  A61K38/45 ,  A61K48/00

    摘要： The present invention relates to methods of treating neoplastic disease whereby gene therapy treatments are employed in combination with a chemotherapy regime. A combinational therapy with anti-neoplastic alkylating agents will optimize host tumor sensitivity to these agents used alone or in combination with O.sup.6 -benzylguanine (BG) or a similar compound or compounds. Hematopoietic cells are infected with a transgene expressing a mutant AGT protein exhibiting DNA repair activity while imparting resistance to BG or a related compound. Introduction of the transduced hematopoietic cell population expressing the mutant AGT protein into the patient in tandem with the chemotherapeutic regime will substantially reduce myelosuppression traditionally associated with the administration of these anti-neoplastic drugs.

    摘要翻译： 本发明涉及治疗肿瘤性疾病的方法，其中基因疗法治疗与化疗方案结合使用。 具有抗肿瘤烷化剂的组合疗法将优化宿主对这些单独使用或与O6-苄基鸟嘌呤（BG）或类似化合物或组合物组合使用的药物的敏感性。 造血细胞用表达具有DNA修复活性的突变型AGT蛋白的转基因感染，同时赋予对BG或相关化合物的抗性。 与化疗方案一起将表达突变型AGT蛋白的转导的造血细胞群导入患者将显着减少传统上与施用这些抗肿瘤药物相关的骨髓抑制。